Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03727789 · ClinicalTrials.gov registry record · Phase 1
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03727789: Clinical Trial Phase 1 study, sponsored by Roswell Park Cancer Institute.
NCT03727789 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03727789, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This phase I trial studies best dose and side effects of CBL0137 in treating patients with extremity melanoma or sarcoma that has spread to other places in the body. Drugs, such as CBL0137, may work by binding to tumor cell deoxyribonucleic acid (DNA) to stop the cell from growing further.
Primary Outcome
The frequency of toxicities will be tabulated by grade across all dose levels. The frequency of toxicities will also be tabulated for the dose estimated to be the maximum tolerated dose.
Interventions
- DRUG FACT Complex-targeting Curaxin CBL0137
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2024-01-16 |
| Phase | Phase 1 |
Why NCT03727789 stopped before completion
NCT03727789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which FACT Complex-targeting Curaxin CBL0137 is the first listed.
NCT03727789 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03727789 about?
NCT03727789 is a clinical study titled "CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma". This phase I trial studies best dose and side effects of CBL0137 in treating patients with extremity melanoma or sarcoma that has spread to other places in the body. Drugs, such as CBL0137, may work by binding to tumor cell deoxyribonucleic acid (DNA) to stop the cell from growing further.
What is the current status of trial NCT03727789?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-07-01. Estimated completion is 2024-01-16.
What interventions are being tested in trial NCT03727789?
The interventions under investigation include: FACT Complex-targeting Curaxin CBL0137 (DRUG).
Who is sponsoring clinical trial NCT03727789?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03727789's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI